| Barchart Demo Center |
$2,02
-0,02 (-0,98%)
en date du mai 31, 2024
en date du mai 31, 2024
| Dernière | 2,02 |
|---|---|
| Variation | -0,02 (-0,98%) |
| Ouverture | 2,03 |
| Clôture précédente | 2,04 |
| Écart (actuel) |
1,98
2,13
|
| Écart 52 semaines |
1,00
7,74
|
| Volume | 15 900 |
| Volume Moyen | 244 955 |
| Secteur | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Nom | Aujourd'hui | 3-mois | 1 an |
|---|---|---|---|
| OGEN |
 -0,98% |
 +45,32% |
-33,55% |
| DJIA |
+1,51% |
-2,09% |
+16,90% |
| S&P 500 |
 +0,80% |
+1,01% |
+25,49% |
Statistiques clef
| BPA Annuel | -8,54 |
|---|---|
| Rendement dividendes | 0,00% |
| Rapport Prix/Bénéfices | N/A |
| Market Capitalization, $K | 8 830 |
| Alpha pondéré | -32,68 |
| Écart-type | -0,07 |
| Marge d'exploitation | N/A |
| Beta | 0,40 |
Taux de croissance
| Cette année | -64,10% | |||
| 1 An(s) | -33,88% | |||
| 3 An(s) | -95,34% | |||
| 5 An(s) | -92,99% | |||
| 10 An(s) | -99,84% |
Opinion
| Vendre | Conserver | Acheter |
Articles récents
Oragenics Appoints William “Frank” Peacock
GlobeNewswire - Wed May 22, 07:00AM CDT
Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department...(version intégrale)
OGEN: 2,02 (-0,02)
Oragenics, Inc. to Host Webinar Panel on Neurotrauma
GlobeNewswire - Fri May 17, 07:00AM CDT
SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal...(version intégrale)
OGEN: 2,02 (-0,02)
Oragenics, Inc. Announces Notification of
Business Wire - Fri Apr 19, 04:50PM CDT
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the N(version intégrale)
OGEN: 2,02 (-0,02)
Oragenics, Inc. Files 10K and Provides Company Update
Business Wire - Mon Apr 01, 08:05AM CDT
Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report(version intégrale)
OGEN: 2,02 (-0,02)
Oragenics Appoints James Kelly MD, Chief Medical
Business Wire - Mon Mar 18, 06:00AM CDT
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James “Jim” Kelly, Neurologist(version intégrale)
OGEN: 2,02 (-0,02)